 |
|
|
| |
Preclinical profiling of ABI-6250, a first-in-class
oral therapeutic candidate for chronic hepatitis D
|
| |
| |
EASL 2025 May 7-10 Amsterdam
Marc P. Windisch, Nuruddin Unchwaniwala, Jinghu Carl Li, Joseph Tan, Ariel Tang, Yanhong Zhu, Francielle Tramontini Gomes de Sousa,
Heidi Contreras, Dinara Azimova, Kirsten Stray, Lewyn Li, Peter Haggie, Gene Schulze, Michael Shen, Jiaxin Yu, Michel Perron,
Michael A. Walker, William E. Delaney, Min Zhong
Assembly Biosciences, Inc., South San Francisco, CA, USA
|
| |
|
|
|
|
|
